Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Submits Femara For Early Adjuvant Treatment Of Breast Cancer

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Novartis is on track for a full range of indications for its breast cancer therapy Femara with a supplemental submission for early adjuvant use.

You may also be interested in...



Femara early adjuvant approval

Novartis' aromatase inhibitor Femara (letrozole) clears FDA Dec. 28 for adjuvant treatment of postmenopausal women with hormone-sensitive early breast cancer. Femara is the only medicine in its class approved for use in that setting as well as in the extended adjuvant setting following tamoxifen, Novartis says. Approval is based on the 8,000-patient Breast International Group (BIG 1-98) study showing an additional 21% reduction in risk of recurrence over tamoxifen (1Pharmaceutical Approvals Monthly August 2005, p. 13). Novartis' promotion of the new indication will be boosted by publication of the pivotal data supporting the sNDA in the Dec. 29 issue of The New England Journal of Medicine...

Novartis Will Expand Femara With Early Adjuvant NDA, Gleevec With Higher Dose

 

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

Topics

UsernamePublicRestriction

Register

PS003006

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel